New drug aims to shrink fatty liver in early trial
NCT ID NCT06836609
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 32 times
Summary
This study tests an experimental drug called ALN-CIDEB in adults with fatty liver disease (MASLD or MASH). The main goal is to check safety and side effects, and also see if it reduces liver fat. About 132 participants will receive either the drug or a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Arizona Liver Health
RECRUITINGChandler, Arizona, 85225, United States
-
Parexel International Early Phase Clinical Unit
RECRUITINGHarrow, London, HA1 3UJ, United Kingdom
-
Richmond Pharmacology Limited
RECRUITINGLondon, Greater London, SE1 1YR, United Kingdom
Conditions
Explore the condition pages connected to this study.